A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Stopped early · Phase 2

Conditions studied: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra

In brief

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Key facts

Study ID

NCT03606174

Run by

Mirati Therapeutics Inc.

People needed

260

Starts

2018-09-11

Expected to finish

2022-08-22

Last updated by the study team

2023-08-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of urothelial carcinoma
• Adequate bone marrow and organ function

You may not qualify if…

• Uncontrolled tumor in the brain
• Unacceptable toxicity with prior checkpoint inhibitor
• Impaired heart function

Where it is running

• The University of Arizona Cancer Center — Tucson, Arizona, United States
• University of California Irvine — Irvine, California, United States
• Rocky Mountain Cancer Centers — Aurora, Colorado, United States
• Yale School of Medicine — New Haven, Connecticut, United States
• SCRI - Florida Cancer Specialists- North Region — St. Petersburg, Florida, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• SCRI - Florida Cancer Specialists - West Palm Beach — West Palm Beach, Florida, United States
• The University of Chicago — Chicago, Illinois, United States
• Indiana University - Melvin & Bren Simon Cancer Center — Indianapolis, Indiana, United States
• Norton Cancer Institute - Broadway — Louisville, Kentucky, United States
• Ochsner Cancer Institute — New Orleans, Louisiana, United States
• Maryland Oncology Hematology, P.A. — Lanham, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri, United States
• GU Research Network/Urology Cancer Center — Omaha, Nebraska, United States
• Comprehensive Cancer Centers of Nevada - Southwest — Las Vegas, Nevada, United States
• New York Oncology Hematology - Albany Medical Center — Albany, New York, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Northwell Health Monter Cancer Center — Lake Success, New York, United States
• NYU Langone Laura & Isaac Perlmutter Cancer Center — New York, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• New York-Presbyterian - Weill Cornell Medical Center — New York, New York, United States
• University of North Carolina - Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
• Duke University Hospital — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.